Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2

Introduction. Sphingosine 1 phosphate (S1P) is a product of the sphingosine kinase 1 (SphK1) enzyme. Increased S1P can lead to tissue fibrosis that is also one of the pathways for developing diabetic cardiomyopathy. Advanced glycation end products (AGEs) increase S1P in cells. The study is aimed at...

Full description

Saved in:
Bibliographic Details
Main Authors: Amir Hossein Heydari, Mojtaba Fathi, Sophia Heydari, Mohammad Esmaeil Heidari
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Cardiovascular Therapeutics
Online Access:http://dx.doi.org/10.1155/2022/7014680
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items